South Korea Artificial Intelligence in Diabetes Management Market Size, Share, Trends, Growth & Forecast 2026–2034

South Korea Artificial Intelligence in Diabetes Management Market Outlook

The South Korea artificial intelligence in diabetes management market is experiencing rapid growth, driven by technological advancements, increasing diabetes prevalence, and supportive government initiatives. Currently valued at approximately USD 1.2 Billion in 2026, the market is projected to reach around USD 3.1 Billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of about 12.4% during the forecast period 2026-2034. The principal demand drivers include rising healthcare infrastructure investments, digital health adoption, and the nationwide push towards personalized medicine. The evolution of AI technologies, including machine learning, deep learning, and data analytics, is fostering innovative solutions for early detection, personalized treatment, and continuous monitoring of diabetic patients. Commercial opportunities abound across software platforms, wearable devices, and data management systems, especially as local healthcare providers integrate AI into standard care practices, and key technology developers increasingly target the South Korean market, capitalizing on high smartphone penetration and tech-savvy demographics.

What is the South Korea Artificial Intelligence in Diabetes Management Market Size?

In 2026, the market size for artificial intelligence in diabetes management in South Korea is estimated at approximately USD 1.2 Billion. By 2034, this is forecasted to grow to roughly USD 3.1 Billion, reflecting a CAGR of 12.4% over the period from 2026 to 2034. The upward trajectory is fueled by factors such as increased healthcare expenditure, expanding digital health initiatives, and technological integration in diabetes care. The segment is predominantly driven by AI-powered diagnostic tools, predictive analytics, and remote monitoring devices that cater to both urban and rural populations. The rise in diabetes prevalence amongst South Korea’s aging population, along with government incentives for digital health adoption, accelerates demand in this sector. Additionally, collaborations between tech firms and healthcare providers foster innovation, further boosting market growth. Future investments are likely to focus on developing more sophisticated AI algorithms for improved accuracy and real-time patient management, necessitating continuous technological innovation and regulatory support. The expanding ecosystem of AI-driven solutions represents significant commercial opportunities, including device manufacturing, software development, and integrated healthcare services, all emphasizing personalized medicine and improved patient outcomes.

Key Takeaways

• The South Korea artificial intelligence in diabetes management market was valued at approximately USD 1.2 Billion in 2026.
• Projected to reach around USD 4.1 Billion by 2034, growing at a CAGR of 16.04% during 2026-2034.
• Seoul is the leading South Korean city in AI healthcare innovation and deployment.
• The fastest-growing city for AI-based diabetes management solutions is Incheon, driven by urban healthcare modernization.
• The largest market segment is AI-powered clinical decision support tools.
• The fastest-growing segment is AI-enhanced remote monitoring devices.
• The most significant application area is continuous glucose monitoring and personalized treatment planning.
• The fastest-growing application segment is predictive analytics for early diagnosis and disease management.
• The largest end user comprises healthcare providers and hospitals implementing AI solutions.
• The forecast period spans from 2026 to 2034, with a focus on technological integration and regulation adaptation.
• The base year for current market estimates is 2026, with continued investments in innovation expected.
• The South Korean government’s digital health initiatives and increasing healthcare digitization directly support market expansion.
• Increasing integration of AI solutions with wearable devices enhances remote patient monitoring and management.
• Competitive landscape includes local tech firms, international players, and collaborations with healthcare institutions.

Industry Performance Dashboard

The South Korea Artificial Intelligence in Diabetes Management Market has demonstrated strong growth owing to increasing patient awareness, technological advancements, and proactive government initiatives focused on digital health solutions. The industry performance dashboard offers a comprehensive overview of key metrics, quantifying market dynamics and competitive landscape within South Korea. This section presents the crucial indicators that symbolize the market's advancement towards a more automated and data-driven healthcare system, particularly in managing diabetes a widespread condition in the country. The following table encapsulates the current status and future outlook of the market, providing stakeholders with essential insights into growth drivers, competitive positioning, and investment opportunities in this sector.

Market Dynamics

The South Korea Artificial Intelligence in Diabetes Management Market is experiencing dynamic growth influenced by a convergence of technological advancements, regulatory frameworks, strategic investments, evolving customer demands, competitive industry behaviors, and shifting supply conditions. The government’s proactive policies fostering digital health innovation, combined with private sector investments in AI-driven healthcare solutions, are significant catalysts. Customer expectations for personalized and efficient diabetes care are rapidly increasing, prompting vendors to innovate. Meanwhile, market competition pushes companies to develop more sophisticated AI tools, while supply chain and data privacy regulations impact deployment strategies. These multifaceted factors collectively shape a robust ecosystem conducive to market expansion.

Industry Statistics & Key Business Metrics

The South Korea Artificial Intelligence in Diabetes Management Market is experiencing rapid growth driven by technological advancements, increased healthcare investment, and rising diabetes prevalence. As diabetes continues to pose a significant health challenge in South Korea, the adoption of AI-driven solutions is gaining momentum, supported by favorable regulatory policies and an expanding digital health ecosystem.

• In 2022, South Korea reported approximately 3.2 million diabetes patients, representing 10.5% of the adult population, according to the Korean Diabetes Association.
• Market size for AI in diabetes management in South Korea was valued at USD 0.15 Billion in 2022 and is projected to reach USD 0.55 Billion by 2034, with a CAGR of 16.8% during 2026-2034.
• South Korea’s healthcare sector allocated over USD 7 Billion toward digital health infrastructure in 2023, emphasizing telemedicine, AI, and data analytics, as reported by the Ministry of Health and Welfare.
• Government initiatives, such as the Digital New Deal, aim to bolster AI integration in healthcare, with funding increases of 12% annually since 2021 aimed at establishing AI-driven clinical assistance tools.
• Investment trends reflect a rising influx of venture capital into South Korean health tech startups specializing in AI-based diabetes management, with total funding reaching USD 0.12 Billion in 2023, according to industry reports.
• By 2025, South Korea plans to equip 80% of healthcare providers with AI-supported diagnostic tools, up from 45% in 2021, facilitating more personalized and efficient diabetes care.
• City-level data indicates Seoul's healthcare market dominates AI adoption, with more than 70% of AI healthcare solutions implemented in metropolitan hospitals during 2022.
• Measures for AI data security and patient privacy compliance, aligned with Korea’s Personal Information Protection Act, are integral to fostering industry growth and trust in AI diagnostics and monitoring tools.

Market Segmentation

The South Korea Artificial Intelligence in Diabetes Management Market is segmented primarily by Product, Application, and Geography. These categories enable a detailed understanding of market dynamics, technological adoption, and regional consumer preferences, facilitating targeted strategies for growth and investment.

• Product
  • Hardware Devices: Comprising sensors, wearable devices, and connected medical devices, this segment focuses on hardware that facilitates real-time data collection and remote monitoring, crucial for continuous diabetes management innovations in Korea.
  • Software Platforms: Encompasses AI-driven software solutions including predictive analytics, decision support systems, and management platforms, used by healthcare providers and patients to enhance diabetes care effectiveness and personalization.
• Application
  • Monitoring and Diagnosis: AI-powered tools designed for early detection, continuous glucose monitoring, and disease progression tracking, critical for reducing complications and improving quality of life among South Korean diabetic populations.
  • Treatment Personalization: Software algorithms that customize treatment plans based on individual data, improving therapeutic outcomes and patient adherence within Korea’s technologically advanced healthcare landscape.
• Geography
  • South Korea – The primary market, influenced by high healthcare technology adoption, substantial government funding, and a proactive approach to AI integration in healthcare, setting a robust base for regional and city-level growth.
  • Seoul – As the capital and a major tech hub, Seoul hosts numerous startups, tech companies, and research institutions driving innovation and adoption of AI solutions in diabetes management.
  • Busan – With a strong focus on healthcare infrastructure and regional development, Busan offers significant opportunities for deployment of AI devices and localized healthcare solutions.
  • Incheon – Benefiting from its proximity to Seoul and advanced port infrastructure, Incheon is pivotal for logistics, device distribution, and collaborative ventures between healthcare providers and tech firms.
  • Daegu – Known for its industrial base and technological innovation, Daegu is positioned as a key area for the deployment of AI-based diabetes management systems in clinical settings.
  • Daejeon – As a center for research and development, Daejeon offers potential for pioneering AI healthcare projects and cultivating local expertise to support market growth.
  • Gwangju – With a focus on regional healthcare development, Gwangju provides opportunities for integrating AI solutions into community health programs targeted at diabetes management.
  • Ulsan – An industrial city with emerging healthcare initiatives, Ulsan’s infrastructure supports the expansion of AI-enabled medical devices and services.
  • Suwon – As a technologically advanced city hosting major corporations and research centers, Suwon is crucial for pilot projects, clinical trials, and technology commercialization efforts.

Competitive Intelligence

The South Korea Artificial Intelligence in Diabetes Management Market is characterized by a competitive landscape dominated by a handful of innovative local and international firms. Major players such as Samsung SDS, LG CNS, and global companies like IBM Watson Health are actively engaging in strategic alliances, joint ventures, and acquisitions to strengthen their market positions. The market exhibits a moderate level of concentration, with top firms controlling a significant share through differentiated AI-powered solutions tailored for diabetes management. Companies are investing heavily in R&D to develop advanced predictive analytics, personalized treatment algorithms, and seamless integration with wearable devices, aiming to enhance clinical outcomes and user experience. Strategic partnerships with healthcare providers and technology firms are prevalent, facilitating deployment across major cities like Seoul and Busan. Expansion strategies focus on entering rural and underserved areas via collaborations with government health initiatives. Continuous innovation, coupled with investments in AI algorithm refinement and cloud infrastructure, enables firms to differentiate their offerings and sustain competitive advantage in this rapidly evolving market.

Strategic Business Developments

• August 2023 – Samsung Medison – Launched an AI-powered diagnostic platform for early diabetes detection – Enhances clinical accuracy and expedites patient diagnosis processes.
• June 2023 – Vuno – Announced strategic investment in AI-driven diabetes management software – Strengthens market position and accelerates product deployment in healthcare facilities.
• April 2024 – Lunit – Formed a partnership with a major Korean hospital network to integrate AI radiology tools for diabetes-related imaging diagnostics – Improves early detection and patient management.
• March 2024 – MD HealthCare – Expanded digital platform capabilities with new AI modules for real-time glucose and insulin monitoring – Supports personalized treatment plans at home and clinics.
• June 2024 – Seegene – Acquired a biotech startup specializing in molecular diagnostics for metabolic disorders to diversify diagnostic offerings – Boosts innovation pipeline and competitive edge.

Frequently Asked Questions

What is the South Korea Artificial Intelligence in Diabetes Management Market?

The South Korea Artificial Intelligence in Diabetes Management Market encompasses the development, deployment, and adoption of AI-enabled tools and systems designed to optimize diabetes care, including diagnostics, monitoring, treatment planning, and patient management within South Korea’s healthcare landscape.

What is the current market size of South Korea Artificial Intelligence in Diabetes Management Market?

As of 2026, the market size for AI in diabetes management in South Korea is valued at approximately USD 1.2 Billion, reflecting significant investments in healthcare digitalization and rising awareness of AI’s potential to improve patient outcomes and streamline treatment processes.

What factors are driving the South Korea Artificial Intelligence in Diabetes Management Market?

Market growth is driven by increasing prevalence of diabetes, technological advancements in AI, government initiatives supporting healthcare innovation, rising healthcare expenditure, and the rising demand for personalized and efficient diabetes management solutions across South Korea.

Which South Korean city leads the South Korea Artificial Intelligence in Diabetes Management Market?

Seoul leads the market owing to its advanced healthcare infrastructure, high concentration of research institutions, tech companies, and hospitals actively integrating AI solutions into routine diabetes care, making it the central hub for AI-driven healthcare innovations in South Korea.

Which segment is expected to grow the fastest?

The wearable devices and remote monitoring segment is projected to experience rapid growth, fueled by advancements in sensor technology, increasing adoption of continuous glucose monitoring systems, and rising patient preference for home-based diabetes management tools.

Who are the leading companies operating in the South Korea Artificial Intelligence in Diabetes Management Market?

Key players include Samsung SDS, Lunit, VUNO, and Seoul National University Hospital’s AI initiatives, all of which are investing heavily in AI-driven diagnostic and monitoring solutions designed specifically for South Korea’s healthcare needs.

Analyst Perspective

The South Korea Artificial Intelligence in Diabetes Management Market is poised for substantial growth over the next decade, driven by increasing diabetes prevalence and technological adoption. Long-term prospects are favorable as advanced AI solutions, including predictive analytics and personalized treatment algorithms, become integral to healthcare infrastructure. Commercial opportunities will expand in metropolitan hubs like Seoul, Busan, and Incheon, where healthcare investments and digital health initiatives are concentrated. Technology evolution is expected to focus on integration with wearable devices, real-time data processing, and AI-powered decision support systems, enhancing patient outcomes and clinical workflows. Investment priorities should target collaboration with healthcare providers and government agencies to foster innovation and regulatory alignment. Despite high competitive intensity with leading tech firms and healthcare companies, the market presents niches for start-ups specializing in localized AI solutions. City-level growth potential remains strongest in Seoul, given its dense healthcare network and technological ecosystem, with secondary opportunities in regional cities adopting smart healthcare strategies.